Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Sabha, Nesrin ^a   Au, Karolyn ^a   Agnihotri, Sameer ^a   Singh, Sanjay ^a   Mangat, Rupinder ^a   Guha, Abhijit ^a   Zadeh, Gelareh ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ACOUSTIC NEURINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; GENE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NF2 GENE; NULL ALLELE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC; PYRIMIDINES;

EID: 84862679500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039412     Document Type: Article

References (24)

1. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, et al. (2007) Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro-Oncology 9: 447-53.
2. Johnson WD, Loredo LN, Slater JD, (2008) Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus 24: E2.
3. Martin TPC, Tzifa K, Kowalski C, Holder RL, Walsh R, et al. (2008) Conservative versus primary surgical treatment of acoustic neuromas: a comparison of rates of facial nerve and hearing preservation. Clin Otolaryngology 33: 228-235.
4. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate neurofibromatosis 2 tumor suppressor. Cell 72: 791-800.
5. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515-521.
6. Bretscher A, Edwards K, Fehon RG, (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-99.
7. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, et al. (2000) Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14: 1617-1630.
8. Rong R, Tang X, Gutmann DH, Ye K, (2004) Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA 101: 18200-5.
9. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO, (2008) Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68: 5236-5245.
10. Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, et al. (2009) Human schwannomas express activated platelet-derived growth factor receptors and c-KIT and are growth inhibited by Gleevec (imatinib mesylate). Cancer Res 69: 5099-5107.
11. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM 344: 1031-7.
12. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandes Reese S, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. NEJM 344: 1038-42.
13. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. NEJM 347: 481-7.
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 347: 472-80.
15. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 7: 129-141.
16. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, et al. (2010) Extended kinase profile and properties of the protein kinase inhibitor Nilotinib. Biochim Biophys Acta 1804: 445-453.
17. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. NEJM 354: 2542-51.
18. Tanaka C, Yin OQP, Sethuraman V, Smith T, Wang X, et al. (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clinical Pharmacol Ther 87: 197-203.
19. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, et al. (2002) Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol. Mar 20(3): 475-82.
20. Ammoun S, Schmid M, Triner J, Manley P, Clemens Oliver Hanemann, (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncology 13(7): 759-766.
21. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, et al. (2009) NF2/Merlin is a novel negative regulator of mTOR Complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Bio 29: 4250-61.
22. Park CS, Schneider IC, Haugh JM, (2003) Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. J Biol Chem 278: 37064-72.
23. Lepont P, Stickney JT, Foster LA, Meng JJ, Hennigan RF, et al. (2008) Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res. 1 637(1-2): 142-51.
24. Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, et al. (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol. 23(6): 1493-500.